Medical professionals are hailing groundbreaking results from an international clinical trial that demonstrate a triple-action cancer injection's ability to completely eradicate tumors in some patients. The results, presented recently at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, offer a new glimmer of hope for those with treatment-resistant diseases.
A New Frontier in Oncology
The trial spanned 11 countries, including the UK, focusing on patients whose cancer had either returned or spread, and who had failed to respond to conventional treatments. The injection, known as amivantamab, showed dramatic results: more than a third of patients saw their tumors shrink within weeks, and in 15 cases, the drug melted the tumors away entirely.
The study focused on 102 patients suffering from head and neck cancer—the world's sixth most common cancer. Out of these, 43 patients saw their tumors shrink or disappear completely. Researchers further noted that the injection has shown similarly promising results in patients battling lung cancer.
The Three-Pronged Attack
Developed by Johnson & Johnson, amivantamab utilizes a sophisticated "smart" mechanism to target cancer in three distinct ways:
- Blocking EGFR: It inhibits epidermal growth factor receptors, proteins that typically help tumors grow.
- Blocking MET: It disrupts the MET pathway, which cancer cells often use to bypass and escape standard treatments.
- Immune Activation: It stimulates the body's own immune system to identify and attack the tumor.
Professor Kevin Harrington, a consultant oncologist at London's Royal Marsden NHS foundation trust and professor at the Institute of Cancer Research (ICR), described the responses as "unprecedentedly strong," particularly for patients whose disease had become resistant to both chemotherapy and immunotherapy.
Real-World Impact
The human impact of this innovation is exemplified by patients like Carl Walsh, 56. Diagnosed with tongue cancer in May 2024, Walsh found that traditional chemotherapy and immunotherapy were unsuccessful. After joining the OrigAMI-4 trial in July 2025, he has since undergone 17 cycles of treatment and reports significant progress.
Looking ahead, amivantamab is currently being evaluated in approximately 60 clinical trials. While the primary focus remains on lung cancer, researchers are expanding the scope to include colorectal, brain, and gastric cancers, potentially benefiting thousands of patients globally each year.
Reference(s):
Cancer jab eradicates tumors entirely in some trial patients
cgtn.com
